Table 4 Epigenetic drugs approved by the FDA.
From: Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Compound | Synonym | Clinical name | Condition | Approved year | Company |
|---|---|---|---|---|---|
Azacitidine | 5-Azacitidine, 5-Aza-CR | Vidaza | MDS | U.S. FDA (2004) | Pharmion Corporation |
5-Aza-2′-deoxycytidine | 5-Aza-CdR, decitabine | Dacogen | MDS | U.S. FDA (2006) | Janssen Pharmaceuticals |
Suberoylanilide hydroxamic acid (SAHA) | Vorinostat | Zolinza | CTCL | U.S. FDA (2006) | Merck |
Romidepsin | Depsipeptide, FK-229, FR901228 | Istodax | CTCL | U.S. FDA (2009) | Celgene |
Belinostat | PXD101 | Beleodaq | PTCL | U.S. FDA (2014) | TopoTarget |
Panobinostat | LBH589 | Farydak | Multiple myeloma | U.S. FDA (2015) | Novartis |
Chidamide | Tucidinostat, HBI-8000 | Epidaza | PTCL | China FDA (2015) | Chipscreen Biosciences |
